Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.
Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.
Am J Prev Med. 2013 Apr;44(4):330-338. doi: 10.1016/j.amepre.2012.11.027.
In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9-26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group.
To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18-26 years.
Data from the 2010 National Health Interview Survey were analyzed in 2011.
In 2010, HPV vaccination initiation among men aged 18-26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18-26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV.
HPV vaccination initiation among men aged 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18-26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage.
2009 年，美国食品药品监督管理局批准四价人乳头瘤病毒（HPV）疫苗用于 9-26 岁男性/男童。2009 年，免疫实践咨询委员会（ACIP）提供了一项许可建议，允许为该人群接种 HPV 疫苗。
评估 HPV 疫苗接种启动率和覆盖率，评估 18-26 岁男性对 HPV 和 HPV 疫苗的认识，并确定与这种认识相关的独立因素。
对 2010 年全国健康访谈调查的数据进行了分析。
2010 年，18-26 岁男性 HPV 疫苗接种启动率为 1.1%。在该年龄组接受采访的 1741 名男性中，近一半听说过 HPV（51.8%）。总体而言，约三分之一的男性听说过 HPV 疫苗（34.8%）。与 18-26 岁男性对 HPV 和 HPV 疫苗的认识较高相关的独立因素包括非西班牙裔白人种族/民族；较高的教育水平；美国出生；更多的医生接触；私人医疗保险；接种其他疫苗；报告与性传播疾病（包括 HIV）相关的风险行为。
2010 年，18-26 岁男性 HPV 疫苗接种启动率较低。HPV 和 HPV 疫苗的知晓率也较低，需要向男性传达这方面的信息。自 2011 年 12 月 ACIP 发布了 HPV4 疫苗在男性/男童中常规使用的建议以来，继续监测 18-26 岁男性 HPV 疫苗接种率对于评估疫苗接种活动、规划和实施增加覆盖率的策略非常有用。
